FDA approves alectinib as adjuvant treatment
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer.
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer.
For those going through cancer treatment, it can be hard to not only find something that makes the body feel good, but tastes good, too.
Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women…
Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy with
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women…
Pancreatic Cancer statistics
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
With an FDA orphan drug designation now granted to IGNK001, clinical trials investigating the agent in acute myeloid leukemia are planned to initiate in the…
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.